New migraine nasal spray enters first human safety trial
NCT ID NCT07016516
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new nasal spray called PRT-064040 in 80 healthy Chinese adults to see if it is safe and how the body processes it. Participants received either a single dose or seven daily doses of the spray or a placebo. The study does not yet test if the spray helps migraines, but it is a first step toward a potential new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRT-064040 nasal spray
What this could lead to
If this early study shows the drug is safe, it could lead to a new nasal spray option for treating migraine attacks.
What could go wrong
This is a very early Phase 1 trial in healthy people, not migraine patients. It only tests safety and how the drug moves through the body, not whether it actually works for migraines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Hospital of Changsha
Changsha, Hunan, China